27Nov 2023
Comparative Study of the Efficacy of Anti-CGRP monoclonal antibodies on Migraineurs

Comparative Study of the Efficacy of Anti-CGRP monoclonal antibodies on Migraineurs

This study compared the clinical effectiveness of three anti-CGRP monoclonal antibodies (mAbs) – fremanezumab, erenumab, and galcanezumab – in treating migraines. Over 12 months, 160 migraineurs were treated and assessed for migraine frequency, intensity, and medication intake. After a one-month suspension and three-month reprisal, no significant differences were found in the efficacy of the three mAbs. However, in chronic migraineurs, galcanezumab showed a higher response rate during the suspension period compared to fremanezumab and erenumab. Fremanezumab demonstrated a higher response rate in high-frequency episodic migraineurs at the 12-month follow-up compared to galcanezumab and erenumab.

  • #general medicine

Like

Save

Share